Molecular diagnostics offers a powerful new tool to help oncologists and pathologists study the genetic causes of cancer as well as the potential of targeted therapies, opening the door to the promising potential of personalized medicine. For cancer researchers conducting mechanism studies, biomarker screening and validation, and therapeutic target discovery, Novogene’s NovoPMTM cancer panel is a cost-effective technology that enriches specific regions or targeted genes through probe hybridization. More affordable than whole-genome and whole-exome sequencing to identify variants underlying the pathogenesis of cancer, NovoPMTM cancer panel is available for both tissue and liquid biopsy. As of August 2016, Novogene has applied its NovoPMTM cancer panel to 3,848 tumor tissue samples and to 2,122 liquid biopsy samples.
Novogene NovoPMTM cancer panel for solid tumors is a comprehensive genetic analysis that simultaneously sequences the coding region of 483 cancer-related genes and selected introns from 19 genes. Custom panels are also available based on your specific request. The panel covers most major cancers (lung, colon, esophageal, gastric, breast, etc.), examining selected genes based on National Comprehensive Cancer Network (NCCN) guidelines for your basic research in support of personalized medicine.